1
|
Suto W, Sakai H, Chiba Y. Sustained exposure to prostaglandin D 2 augments the contraction induced by acetylcholine via a DP 1 receptor-mediated activation of p38 in bronchial smooth muscle of naive mice. J Smooth Muscle Res 2020; 55:1-13. [PMID: 30918168 PMCID: PMC6433600 DOI: 10.1540/jsmr.55.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Prostaglandin D2 (PGD2), one of the key lipid mediators of
allergic airway inflammation, is increased in the airways of asthmatics.
However, the role of PGD2 in the pathogenesis of asthma is not fully
understood. In the present study, effects of PGD2 on smooth muscle
contractility of the airways were determined to elucidate its role in the
development of airway hyperresponsiveness (AHR). In a murine model of allergic
asthma, antigen challenge to the sensitized animals caused a sustained increase
in PGD2 levels in bronchoalveolar lavage (BAL) fluids, indicating
that smooth muscle cells of the airways are continually exposed to
PGD2 after the antigen exposure. In bronchial smooth muscles
(BSMs) isolated from naive mice, a prolonged incubation with PGD2
(10−5 M, for 24 h) induced an augmentation of contraction induced
by acetylcholine (ACh): the ACh concentration-response curve was significantly
shifted upward by the 24-h incubation with PGD2. Application of
PGD2 caused phosphorylation of ERK1/2 and p38 in cultured BSM
cells: both of the PGD2-induced events were abolished by laropiprant
(a DP1 receptor antagonist) but not by fevipiprant (a DP2
receptor antagonist). In addition, the BSM hyperresponsiveness to ACh induced by
the 24-h incubation with PGD2 was significantly inhibited by
co-incubation with SB203580 (a p38 inhibitor), whereas U0126 (a ERK1/2
inhibitor) had no effect on it. These findings suggest that prolonged exposure
to PGD2 causes the BSM hyperresponsiveness via the DP1
receptor-mediated activation of p38. A sustained increase in PGD2 in
the airways might be a cause of the AHR in allergic asthmatics.
Collapse
Affiliation(s)
- Wataru Suto
- Department of Physiology and Molecular Sciences, School of Pharmacy, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan
| | - Hiroyasu Sakai
- Department of Biomolecular Pharmacology, School of Pharmacy, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan
| | - Yoshihiko Chiba
- Department of Physiology and Molecular Sciences, School of Pharmacy, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan
| |
Collapse
|
2
|
Yang Y, Chen Q, Zhao Q, Luo Y, Xu Y, Du W, Wang H, Li H, Yang L, Hu C, Zhang J, Li Y, Xia H, Chen Z, Ma J, Tian X, Yang J. Inhibition of COX2/PGD2-Related Autophagy Is Involved in the Mechanism of Brain Injury in T2DM Rat. Front Cell Neurosci 2019; 13:68. [PMID: 30873010 PMCID: PMC6400968 DOI: 10.3389/fncel.2019.00068] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2018] [Accepted: 02/11/2019] [Indexed: 12/21/2022] Open
Abstract
The present study was designed to observe the effect of COX2/PGD2-related autophagy on brain injury in type 2 diabetes rats. The histopathology was detected by haematoxylin–eosin staining. The learning and memory functions were evaluated by Morris water maze. The levels of insulin and PGD2 were measured by enzyme-linked immunosorbent assay. The expressions of COX2, p-AKT(S473), p-AMPK(T172), Aβ, Beclin1, LC3BII, and p62 were measured by immunohistochemistry and Western blotting. In model rats, we found that the body weight was significantly decreased, the blood glucose levels were significantly increased, the plasma insulin content was significantly decreased, the learning and memory functions were impaired and the cortex and hippocampus neurons showed significant nuclear pyknosis. The levels of COX2, p-AKT(S473), PGD2, Aβ, Beclin1 and p62 were significantly increased, whereas the expression of p-AMPK(T172) and LC3BII was significantly decreased in the cortex and hippocampus of model rats. In meloxicam-treated rats, the body weight, blood glucose and the content of plasma insulin did not significantly change, the learning and memory functions were improved and nuclear pyknosis was improved in the cortex and hippocampus neurons. The expression of p-AMPK(T172), Beclin1 and LC3BII was significantly increased, and the levels of COX2, p-AKT(S473), PGD2, Aβ, and p62 were significantly decreased in the cortex and hippocampus of meloxicam-treated rats. Our results suggested that the inhibition of COX2/PGD2-related autophagy was involved in the mechanism of brain injury caused by type 2 diabetes in rats.
Collapse
Affiliation(s)
- Yang Yang
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| | - Qi Chen
- Department of Pharmacy, GuiZhou Provincial People's Hospital, Guiyang, China
| | - Quanfeng Zhao
- Department of Pharmacy, Southwest Hospital, First Affiliated Hospital to TMMU, Third Military Medical University (Army Medical University), Chongqing, China
| | - Ying Luo
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| | - Ying Xu
- Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York (SUNY), Buffalo, NY, United States
| | - Weimin Du
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| | - Hong Wang
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| | - Huan Li
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| | - Lu Yang
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| | - Congli Hu
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| | - Jiahua Zhang
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| | - Yuke Li
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| | - Hui Xia
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| | - Zhihao Chen
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| | - Jie Ma
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| | - Xiaoyan Tian
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| | - Junqing Yang
- Department of Pharmacology, Chongqing Medical University, The Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing, China
| |
Collapse
|